Ghrelin Levels in Pancreatic Cancer Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00225745
First received: September 22, 2005
Last updated: February 14, 2014
Last verified: February 2014

September 22, 2005
February 14, 2014
April 2004
October 2013   (final data collection date for primary outcome measure)
To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls [ Time Frame: prior to treatment ] [ Designated as safety issue: No ]
To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls
Complete list of historical versions of study NCT00225745 on ClinicalTrials.gov Archive Site
  • To investigate the role of ghrelin in pathophysiology of cancer cachexia [ Time Frame: prior to treatment ] [ Designated as safety issue: Yes ]
  • To generate hypotheses for future studies and treatment based on the findings [ Time Frame: prior to treatment ] [ Designated as safety issue: No ]
  • To investigate the role of ghrelin in pathophysiology of cancer cachexia
  • To generate hypothese for future studies and treatment based on the findings
Not Provided
Not Provided
 
Ghrelin Levels in Pancreatic Cancer Patients
Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer

The primary outcome measure for this study is plasma ghrelin level.

The primary outcome measure for this study is plasma ghrelin level, and the two primary comparison are:

  • Patients with cachexia versus patients without cachexia
  • Patients with cachexia versus healthy controls
Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Retention:   Samples Without DNA
Description:

Whole Blood

Non-Probability Sample

Pancreatic cancer patients who have not received treatment. Healthy age-matched controls.

Pancreatic Cancer
Procedure: Blood draw
One blood draw prior to first treatment
  • 1
    Pancreatic cancer patients
    Intervention: Procedure: Blood draw
  • 2
    Healthy controls
    Intervention: Procedure: Blood draw
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
April 2014
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological or cytological proof of pancreatic adenocarcinoma
  • The control are will include healthy age-matched patients without cancer
  • The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss
  • Patients must have recovered from any major infections and/or surgical procedures

Exclusion Criteria:

  • Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state
  • Patients on appetite stimulant and those receiving total parenteral nutrition
  • Patients who have undergone gastrectomy or those who have gastric ulcers
  • Patients receiving active chemotherapy
  • No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00225745
DMS 0405
Yes
Dartmouth-Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center
Not Provided
Principal Investigator: J Marc Pipas, MD Dartmouth-Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP